SS
CEROW

Steve Schonfeld’s CERo Therapeutics Warrants CEROW Stock Holding History

Steve Schonfeld’s Portfolio CEROW Stock Details CEROW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-36,000
Closed -$8K – 3078
2022
Q1 		$8K Hold
36,000
– – ﹤0.01% 2436
2021
Q4 		$15K Buy
+36,000
New +$16.6K ﹤0.01% 2008

Other funds holding CEROW

CF
Cantor Fitzgerald New York $9.31B AUM 73.66% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return
MI
MMCAP International Grand Cayman, Cayman Islands $1.18B AUM 50.44% 1-Year Est. Return
SCM
Saba Capital Management New York $3.9B AUM 12.9% 1-Year Est. Return
CSD
Clear Street Derivatives New York $12.4M AUM 1.7% 1-Year Est. Return
LA
Linden Advisors New York $19.3B AUM 1.47% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $665M AUM 95.48% 1-Year Est. Return
CS
Clear Street New York $39.5B AUM 124.03% 1-Year Est. Return
QGA
Q Global Advisors Fort Worth, Texas $157M AUM 29.28% 1-Year Est. Return
CCM
Context Capital Management Lajolla, California $5.15B AUM 1.28% 1-Year Est. Return

Steve Schonfeld's CEROW Position: Q2 2025 in Review

Steve Schonfeld sold out of CERo Therapeutics Warrants (CEROW) in Q2 2025, closing a stake of 15,000 shares — an estimated $217 sold.

Steve Schonfeld first reported a position in CEROW in Q2 2022 and held it in 12 quarters. The position peaked at $4K in Q2 2022. 23 funds tracked by Wall St. Rank hold CEROW as of Q2 2025.

  • Steve Schonfeld reported no remaining CERo Therapeutics Warrants position as of Q2 2025 after selling out during the quarter.
  • Steve Schonfeld sold 15,000 CERo Therapeutics Warrants shares in Q2 2025, an estimated $217.
  • Steve Schonfeld first reported a position in CERo Therapeutics Warrants in Q2 2022 and held it in 12 quarters.
  • Steve Schonfeld's CERo Therapeutics Warrants position peaked at $4K in Q2 2022.
  • 23 funds tracked by Wall St. Rank held CERo Therapeutics Warrants as of Q2 2025.

Based on Schonfeld Strategic Advisors's 13F filing for Q2 2025, filed 14 Aug 2025.